Clinical Trial Update: Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating glutamine in patients with ischemic heart disease following cardiopulmonary bypass has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Ischemic Heart Disease

Drugs mentioned

• Glutamine (glutamine)

Snippet

Sponsor: Meshalkin Research Institute of Pathology of Circulation | Conditions: Coronary Artery Disease | Phase 3 | Status: COMPLETED